The 1.2 billion yuan market for adjuvant hypotension treatment drugs welcomes competitors!

Tianyao Co.
, Ltd.
announced on the evening of November 18 that its subsidiary Tianjin Jinyao Pharmaceutical Co.
, Ltd.
("Jinyao Pharmaceutical") received the approval and issuance of the "Drugs for Norepinephrine Bitartrate Injection" issued by the State Food and Drug Administration.
Supplementary Application Approval Notice", approved the drug to pass the generic drug consistency evaluation
.
Jinyao Pharmaceutical is the second domestic company that has been evaluated, which means that this 1 billion yuan market has ushered in competitors
.
Norepinephrine bitartrate injection can be used for blood pressure control in certain acute hypotensive states (such as pheochromocytosis, sympathectomy, polio, spinal anesthesia, myocardial infarction, sepsis, blood transfusion, and drug reactions).
As an adjuvant treatment for cardiac arrest and severe hypotension
.
For shock caused by hypovolemia, the drug can be used as an adjuvant therapy for blood volume supplementation during emergency treatment to increase blood pressure and temporarily maintain cerebral and coronary perfusion until blood volume supplement therapy takes effect.
It can also be used after cardiac arrest and resuscitation.
Blood pressure is maintained
.
It is understood that norepinephrine bitartrate injection belongs to the category of "National Essential Drug List (2018)", "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2020)" Category A variety, and clinically necessary and easy to be short Medicine
.
From the perspective of market size, the domestic market prospects of norepinephrine bitartrate injection are quite impressive, according to the enlarged version of the hospital data of Minai.
com (including urban public hospitals, county-level public hospitals, urban community hospitals, and township health centers) It is shown that the sales of norepinephrine bitartrate injection in 2019 will be about 1 billion yuan, and the sales in 2020 will be about 1.
2 billion yuan
.
Judging from the situation of the similar drug market, there are currently 7 companies in the domestic market whose norepinephrine bitartrate injections have been approved for listing.
Among them, Grand Pharmaceuticals became the first company to review the product in September this year, and Jinyao Pharmaceuticals is a domestic company.
The second company that passed the consistency evaluation of norepinephrine bitartrate injection
.
Up to now, Jinyao Pharmaceutical has invested about 10 million yuan in research and development expenses in the product consistency evaluation project
.
According to the relevant national policies, the quality and efficacy of drugs that have passed the consistency evaluation are equivalent to the original research drugs.
Appropriate support should be provided in terms of medical insurance payment.
Medical institutions should give priority to purchase and use in clinical practice.

.
At the same time, under the influence of a series of medical reform policies such as mass procurement, medicines that pass the consistency evaluation mean that they get "entry tickets" to participate in centralized procurement
.
Jinyao Pharmaceutical believes that the consistency evaluation of its norepinephrine bitartrate injection will help enhance the market competitiveness of the drug and accumulate experience for the company's follow-up product consistency evaluation work
.
According to data, Tianyao is a pharmaceutical company with a full industrial chain of "raw materials + preparations" with corticosteroids and amino acid drugs as the core
.
It is understood that Tianyao shares actively participate in the consistency evaluation and evaluation.
Since this year, many of its drugs have been reviewed.
In addition to norepinephrine bitartrate injection, the previously reviewed drugs include epinephrine hydrochloride injection and 5 drugs.
specifications methylprednisolone sodium succinate for injection, injection isoniazid, glycerol and fructose and sodium chloride injection, lidocaine hydrochloride injection, injection aminophylline and the like
.